Roche
Search results
At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market.
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland.
Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise ...
Overview of key investor relevant topics addressed by Lonza about its shares, general finance and investor relations services. Learn more Bond Investors and Credit Information
About us. At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of...
We provide life science researchers with the tools they need to develop and test therapeutics, from basic research to final product release. Lonza’s Bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing.
Jul 9, 2024 · Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. It operates through four segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients.
2 days ago · Corporate. 25 Jul 2024. Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin . Lonza has reported sales of CHF 3.1 billion, growing 1.8% CER (-0.7% AER).
Get the latest Lonza Group AG (LONN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
2 days ago · Furthermore, Lonza welcomed its new Chairman of the Board of Directors, Jean-Marc Huët, and announced the appointment of its new CEO Wolfgang Wienand, who joined Lonza on 1 July. Looking to H2 2024, group sales are expected to be higher than H1, reflecting the timing of batch releases and the ramp-up of new facilities in Biologics and Small ...
